NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial.

TPS2606Background: Certain tumor types show dramatic responses to targeted treatments based on demonstration of the corresponding molecular abnormality. The NCI-MATCH study hypothesizes that patients (pts) across a range of histologies whose tumors share molecular abnormalities that have been shown to respond to a targeted treatment may respond to that same treatment, and that responsiveness or resistance may be predictable by concurrent molecular abnormalities. Methods: Pts with refractory solid tumors or lymphomas have molecular profiling on a proximate biopsy, using a validated, locked next generation sequencing (NGS) assay (143 genes; single nucleotide variants, copy number variants and fusions) and selected other molecular assays. The trial will have > 20 phase II targeted treatments (arms). Drugs are provided by various pharmaceutical companies and could be FDA approved or investigational single agents or combinations. The arms are placed under a “master protocol”, allowing new arms to be added to r...